Editorial Comment
The MYD88L265P conundrum in IgM monoclonal gammopathy of undetermined significance
Prashant Kapoor,
Corresponding Author
Prashant Kapoor
Division of Haematology, Mayo Clinic, Rochester, MN, USA
Correspondence: Dr Prashant Kapoor, Division of Haematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
E-mail: [email protected]
Search for more papers by this authorPrashant Kapoor,
Corresponding Author
Prashant Kapoor
Division of Haematology, Mayo Clinic, Rochester, MN, USA
Correspondence: Dr Prashant Kapoor, Division of Haematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
E-mail: [email protected]
Search for more papers by this authorNo abstract is available for this article.
References
- Blade, J. & Rosinol, L. (2006) Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Current Treatment Options in Oncology, 7, 237–245.
- Bustoros, M., Sklavenitis-Pistofidis, R., Kapoor, P., Liu, C.-J., Kastritis, E., Zanwar, S., Fell, G., Abeykoon, J.P., Hornburg, K., Neuse, C.J., Marinac, C.R., Liu, D., Soiffer, J., Gavriatopoulou, M., Boehner, C., Cappuccio, J.M., Dumke, H., Reyes, K., Soiffer, R.J., Kyle, R.A., Treon, S.P., Castillo, J.J., Dimopoulos, M.A., Ansell, S.M., Trippa, L. & Ghobrial, I.M. (2019) Progression risk stratification of asymptomatic waldenström macroglobulinemia. Journal of Clinical Oncology, 37, 1403–1411.
- Hunter, Z.R., Yang, G., Xu, L., Liu, X., Castillo, J.J. & Treon, S.P. (2017) Genomics, Signaling, and Treatment of. Waldenstrom Macroglobulinemia. Journal of Clinical Oncology, 994–1001. Jco2016710814.
- Kapoor, P., Ansell, S.M., Fonseca, R., Chanan-Khan, A., Kyle R.A., Kumar, S.K., Mikhael, J.R., Witzig, T.E., Mauermann, M., Dispenzieri, A, Ailawadhi, S., Stewart, A.K., Lacy, M.Q., Thompson, C.A., Buadi, F.K., Dingli, D., Morice, W.G., Go, R.S., Jevremovic, D., Sher, T., King, R.L., Braggio, E., Novak, A., Roy, V., Ketterling, R.P., Greipp, P.T., Grogan, M., Micallef, I.N., Bergsagel, P.L., Colgan, J.P., Leung, N., Gonsalves, W.I., Lin, Y., Inwards, D.J., Hayman, S.R., Nowakowski, G.S., Johnston, P.B., Russell, S.J., Markovic, S.N., Zeldenrust, S.R., Hwa, Y.L., Lust, J.A., Porrata, L.F., Habermann, T.M., Rajkumar, S.V., Gertz, M.A., Reeder, C.B. (2017) Diagnosis and management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncology, 3, 1257–1265.
- Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Remstein, E.D., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J. 3rd (2003) Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood, 102, 3759–3764.
- Kyle, R.A., Larson, D.R., Therneau, T.M., Dispenzieri, A., Kumar, S., Cerhan, J.R. & Rajkumar, S.V. (2018) Long-term follow-up of monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 378, 241–249.
- Owen, R.G., Treon, S.P., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Pangalis, G.A., San Miguel, J.F., Branagan, A.R. & Dimopoulos, M.A. (2003) Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 110–115.
- Paiva, B., Montes, M.C., Garcia-Sanz, R., Ocio, E.M., Alonso, J., de Las Heras, N., Escalante, F., Cuello, R., de Coca, A.G., Galende, J., Hernandez, J., Sierra, M., Martin, A., Pardal, E., Barez, A., Alonso, J., Suarez, L., Gonzalez-Lopez, T.J., Perez, J.J., Orfao, A., Vidriales, M.B. & San Miguel, J.F. (2014) Multiparameter flow cytometry for the identification of the Waldenstrom's clone in IgM-MGUS and Waldenstrom's Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia, 28, 166–173.
- Paiva, B., Corchete, L.A., Vidriales, M.B., García-Sanz, R., Perez, J.J., Aires-Mejia, I., Sanchez, M., Barcena, P., Alignani, D., Jimenez, C., Sarasquete, M., Mateos, M., Ocio, E.M., Puig, N., Escalante, F., Hernández, J., Cuello, R., García de Coca, A., Sierra, M., Montes, M., González-López, T.J., Galende, J., Bárez, A., Alonso, J., Pardal, E., Orfao, A., Gutierrez, N.C. & San Miguel, J.F. (2015) The cellular origin and malignant transformation of Waldenstrom macroglobulinemia. Blood, 125, 2370–2380.
- Poulain, S., Roumier, C., Decambron, A., Renneville, A., Herbaux, C., Bertrand, E., Tricot, S., Daudignon, A., Galiegue-Zouitina, S., Soenen, V., Theisen, O., Grardel, N., Nibourel, O., Roche-Lestienne, C., Quesnel, B., Duthilleul, P., Preudhomme, C. & Leleu, X. (2013) MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood, 121, 4504–4511.
- Rajkumar, S.V. (2015) Macro-Quest. Blood, 125, 2318–2319.
- S. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, D. Arber, R. Hasserjian & M. LeBeau (eds.) (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised, vol. 2, 4th edn. International Agency for Research on Cancer, Lyon, France.
- Treon, S.P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R.J., Patterson, C.J., Tripsas, C., Arcaini, L., Pinkus, G.S., Rodig, S.J., Sohani, A.R., Harris, N.L., Laramie, J.M., Skifter, D.A., Lincoln, S.E. & Hunter, Z.R. (2012) MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia. New England Journal of Medicine, 367, 826–833.
- Varettoni, M., Arcaini, L., Zibellini, S., Boveri, E., Rattotti, S., Riboni, R., Corso, A., Orlandi, E., Bonfichi, M., Gotti, M., Pascutto, C., Mangiacavalli, S., Croci, G., Fiaccadori, V., Morello, L., Guerrera, M.L., Paulli, M. & Cazzola, M. (2013) Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood, 121, 2522–2528.
- Varettoni, M., Zibellini, S., Boveri, E., Klersy, C., Candido, C., Rattotti, S., Ferretti, V.V., Defrancesco, I., Mangiacavalli, S., Nizzoli, M.E., Flospergher, E., Zerbi, C., Bergamini, F., Benvenuti, P., Brociner, M., Merati, G., Paulli, M. & Arcaini, L. (2019) A risk-stratification model based on the initial concentration of the serum monoclonal protein and the MYD88 mutation status identifies a subset of patients with IgM Monoclonal Gammopathy of Undetermined Significance at high risk of progression to Waldenstrom’s Macroglobulinemia or other lymphoproliferative disorders. British Journal of Haematology. https://doi.org/10.1111/bjh.16086
- Xu, L., Hunter, Z.R., Tsakmaklis, N., Cao, Y., Yang, G., Chen, J., Liu, X., Kanan, S., Castillo, J.J., Tai, Y., Zehnder, J.L., Brown, J.R., Carrasco, R.D., Advani, R., Sabile, J.M., Argyropoulos, K., Lia Palomba, M., Morra, E., Trojani, A., Greco, A., Tedeschi, A., Varettoni, M., Arcaini, L., Munshi, N.M., Anderson, K.C. & Treon, S.P. (2016) Clonal architecture of CXCR16 WHIM-like mutations in Waldenström macroglobulinaemia. British Journal of Haematology, 172, 735–744.
Citing Literature
